Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions: B-Cell Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia Interventions: Drug: Tecartus Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Kite, A Gilead Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Research | Study